tetano
Editor, Senior Moderator
Diabetes Obes Metab
. 2021 Feb 2.
doi: 10.1111/dom.14324. Online ahead of print.
Use of Dipeptidyl Peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: a propensity score analysis from the CORONADO study
Ronan Roussel[SUP] 1 [/SUP], Patrice Darmon[SUP] 2 [/SUP], Matthieu Pichelin[SUP] 3 [/SUP], Thomas Goronflot[SUP] 4 [/SUP], Yawa Abouleka[SUP] 1 [/SUP], Leila Ait Bachir[SUP] 5 [/SUP], Ingrid Allix[SUP] 6 [/SUP], Deborah Ancelle[SUP] 7 [/SUP], Sara Barraud[SUP] 8 9 [/SUP], Lyse Bordier[SUP] 10 [/SUP], Aur?lie Carlier[SUP] 1 [/SUP], Nicolas Chevalier[SUP] 11 12 [/SUP], Christine Coffin-Boutreux[SUP] 13 [/SUP], Emmanuel Cosson[SUP] 14 [/SUP], Anne Dorange[SUP] 15 [/SUP], Olivier Dupuy[SUP] 16 [/SUP], Pierre Fontaine[SUP] 17 [/SUP], B?n?dicte Fremy[SUP] 18 [/SUP], Florence Galtier[SUP] 19 [/SUP], Natacha Germain[SUP] 20 [/SUP], Anne-Marie Guedj[SUP] 21 [/SUP], Etienne Larger[SUP] 22 [/SUP], St?phanie Laugier-Robiolle[SUP] 23 [/SUP], Bruno Laviolle[SUP] 24 [/SUP], Lisa Ludwig[SUP] 25 [/SUP], Arnaud Monier[SUP] 26 [/SUP], Nathana?lle Montanier[SUP] 27 [/SUP], Philippe Moulin[SUP] 28 [/SUP], Isabelle Moura[SUP] 29 [/SUP], Ga?tan Prevost[SUP] 30 [/SUP], Yves Reznik[SUP] 31 [/SUP], Nadia Sabbah[SUP] 32 [/SUP], Pierre-Jean Saulnier[SUP] 33 [/SUP], Pierre Serusclat[SUP] 34 [/SUP], Camille Vatier[SUP] 35 [/SUP], Matthieu Wargny[SUP] 4 [/SUP], Samy Hadjadj[SUP] 3 [/SUP], Pierre Gourdy[SUP] 36 [/SUP], Bertrand Cariou[SUP] 3 [/SUP], CORONADO investigators
Collaborators, Affiliations
Abstract
Aims: Dipeptidyl Peptidase-4 (DPP-4), the target of oral antidiabetic drugs DDP-4 inhibitors, has been suggested to be involved in the pathogenesis of coronavirus infections, including COVID-19. It is unclear whether the routine use of DPP-4 inhibitors increases the severity of COVID-19 in people with type 2 diabetes (T2D). Our purpose was to investigate the association between routine use of DPP-4 inhibitors and the severity of COVID-19 infection in a large multicentric study.
Material and methods: This study was a secondary analysis of the CORONADO study on 2449 patients with T2D hospitalized for COVID-19 in 68 French centres. The composite primary endpoint combined tracheal intubation for mechanical ventilation and death within 7 days of admission. Stabilized weights were computed for patients based on propensity score (DPP-4 inhibitors users vs non-users) and were used into multivariable logistic regression models to estimate Average Treatment effect in the Treated as Inverse Probability of Treatment Weighting (IPTW).
Results: 596 participants were under DPP-4 inhibitors before admission to hospital (24.3%). The primary outcome occurred at similar rates in users and non-users of DPP-4 inhibitors (27.7% vs 28.6%, P=0.68). In propensity analysis, the IPTW-adjusted models showed no significant association between use of DPP-4 inhibitors and the primary outcome within day 7 (OR [95%CI]: 0.95 [0.77-1.17]) or day 28 (OR [95%CI]: 0.96 [0.78-1.17]). Similar neutral findings were found between use of DPP-4 inhibitors and the risk of tracheal intubation and death.
Conclusions: These data support the safety of DPP-4 inhibitors for diabetes management during the COVID-19 pandemic and they should not be discontinued. This article is protected by copyright. All rights reserved.
. 2021 Feb 2.
doi: 10.1111/dom.14324. Online ahead of print.
Use of Dipeptidyl Peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: a propensity score analysis from the CORONADO study
Ronan Roussel[SUP] 1 [/SUP], Patrice Darmon[SUP] 2 [/SUP], Matthieu Pichelin[SUP] 3 [/SUP], Thomas Goronflot[SUP] 4 [/SUP], Yawa Abouleka[SUP] 1 [/SUP], Leila Ait Bachir[SUP] 5 [/SUP], Ingrid Allix[SUP] 6 [/SUP], Deborah Ancelle[SUP] 7 [/SUP], Sara Barraud[SUP] 8 9 [/SUP], Lyse Bordier[SUP] 10 [/SUP], Aur?lie Carlier[SUP] 1 [/SUP], Nicolas Chevalier[SUP] 11 12 [/SUP], Christine Coffin-Boutreux[SUP] 13 [/SUP], Emmanuel Cosson[SUP] 14 [/SUP], Anne Dorange[SUP] 15 [/SUP], Olivier Dupuy[SUP] 16 [/SUP], Pierre Fontaine[SUP] 17 [/SUP], B?n?dicte Fremy[SUP] 18 [/SUP], Florence Galtier[SUP] 19 [/SUP], Natacha Germain[SUP] 20 [/SUP], Anne-Marie Guedj[SUP] 21 [/SUP], Etienne Larger[SUP] 22 [/SUP], St?phanie Laugier-Robiolle[SUP] 23 [/SUP], Bruno Laviolle[SUP] 24 [/SUP], Lisa Ludwig[SUP] 25 [/SUP], Arnaud Monier[SUP] 26 [/SUP], Nathana?lle Montanier[SUP] 27 [/SUP], Philippe Moulin[SUP] 28 [/SUP], Isabelle Moura[SUP] 29 [/SUP], Ga?tan Prevost[SUP] 30 [/SUP], Yves Reznik[SUP] 31 [/SUP], Nadia Sabbah[SUP] 32 [/SUP], Pierre-Jean Saulnier[SUP] 33 [/SUP], Pierre Serusclat[SUP] 34 [/SUP], Camille Vatier[SUP] 35 [/SUP], Matthieu Wargny[SUP] 4 [/SUP], Samy Hadjadj[SUP] 3 [/SUP], Pierre Gourdy[SUP] 36 [/SUP], Bertrand Cariou[SUP] 3 [/SUP], CORONADO investigators
Collaborators, Affiliations
- PMID: 33528920
- DOI: 10.1111/dom.14324
Abstract
Aims: Dipeptidyl Peptidase-4 (DPP-4), the target of oral antidiabetic drugs DDP-4 inhibitors, has been suggested to be involved in the pathogenesis of coronavirus infections, including COVID-19. It is unclear whether the routine use of DPP-4 inhibitors increases the severity of COVID-19 in people with type 2 diabetes (T2D). Our purpose was to investigate the association between routine use of DPP-4 inhibitors and the severity of COVID-19 infection in a large multicentric study.
Material and methods: This study was a secondary analysis of the CORONADO study on 2449 patients with T2D hospitalized for COVID-19 in 68 French centres. The composite primary endpoint combined tracheal intubation for mechanical ventilation and death within 7 days of admission. Stabilized weights were computed for patients based on propensity score (DPP-4 inhibitors users vs non-users) and were used into multivariable logistic regression models to estimate Average Treatment effect in the Treated as Inverse Probability of Treatment Weighting (IPTW).
Results: 596 participants were under DPP-4 inhibitors before admission to hospital (24.3%). The primary outcome occurred at similar rates in users and non-users of DPP-4 inhibitors (27.7% vs 28.6%, P=0.68). In propensity analysis, the IPTW-adjusted models showed no significant association between use of DPP-4 inhibitors and the primary outcome within day 7 (OR [95%CI]: 0.95 [0.77-1.17]) or day 28 (OR [95%CI]: 0.96 [0.78-1.17]). Similar neutral findings were found between use of DPP-4 inhibitors and the risk of tracheal intubation and death.
Conclusions: These data support the safety of DPP-4 inhibitors for diabetes management during the COVID-19 pandemic and they should not be discontinued. This article is protected by copyright. All rights reserved.